Results 11 to 20 of about 182,063 (264)

Interstitial Lung Disease

JAMA
Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure.
Kanchustambham V, Sankari A.
openaire   +4 more sources

Interstitial lung disease [PDF]

European Respiratory Review, 2013
This article reviews the most important articles published in interstitial lung disease, as reviewed during the Clinical Year in Review session at the 2012 annual European Respiratory Society Congress in Vienna, Austria.Since the recent international guidelines for the management of idiopathic pulmonary fibrosis (IPF), important new evidence is ...
openaire   +4 more sources

Comorbidities in interstitial lung diseases

European Respiratory Review, 2017
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted.
George A. Margaritopoulos, Katerina M. Antoniou, Athol U. Wells   +2 more
doaj   +1 more source

Personalised medicine in interstitial lung diseases

European Respiratory Review, 2018
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised ...
Maria A. Kokosi, George A. Margaritopoulos, Athol U. Wells   +2 more
doaj   +1 more source

Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome

ERJ Open Research, 2021
Introduction Idiopathic pulmonary fibrosis (IPF) prognosis is heterogeneous despite antifibrotic treatment. Cluster analysis has proven to be a useful tool in identifying interstitial lung disease phenotypes, which has yet to be performed in IPF. The aim
Jaume Bordas-Martínez, Ricard Gavaldà, Jessica G. Shull, Vanesa Vicens-Zygmunt, Lurdes Planas-Cerezales, Guadalupe Bermudo-Peloche, Salud Santos, Neus Salord, Carmen Monasterio, Maria Molina-Molina, Guillermo Suarez-Cuartin   +10 more
doaj   +1 more source

Genetic Interstitial Lung Disease [PDF]

Clinics in Chest Medicine, 2012
The interstitial lung diseases (ILDs), or diffuse parenchymal lung diseases, are a heterogeneous collection of more than 100 different pulmonary disorders that affect the tissue and spaces surrounding the alveoli. Patients affected by ILD usually present with shortness of breath or cough; for many, there is evidence of pulmonary restriction, decreased ...
Megan Stuebner, Devine, Christine Kim, Garcia   +1 more
openaire   +2 more sources

Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts

Frontiers in Medicine, 2023
Within the wide scope of interstitial lung diseases (ILDs), familial pulmonary fibrosis (FPF) is being increasingly recognized as a specific entity, with earlier onset, faster progression, and suboptimal responses to immunosuppression.
Stefan Cristian Stanel, Stefan Cristian Stanel, Jack Callum, Pilar Rivera-Ortega   +3 more
doaj   +1 more source

Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity

Revista Portuguesa de Pneumologia (English Edition), 2017
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years.
E.B. Boerner, U. Costabel, T.E. Wessendorf, D. Theegarten, F. Bonella   +4 more
doaj   +1 more source

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults

BMC Pulmonary Medicine, 2019
Background Diffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT).
Anna Stainer, Alex Rice, Anand Devaraj, Joseph Luke Barnett, Jacqueline Donovan, Maria Kokosi, Andrew Gordon Nicholson, Tom Cairns, Athol Umfrey Wells, Elisabetta Augusta Renzoni   +9 more
doaj   +1 more source

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

Frontiers in Medicine, 2020
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline.
Sachin Chaudhary, Bhupinder Natt, Christian Bime, Kenneth S. Knox, Kenneth S. Knox, Marilyn K. Glassberg   +5 more
doaj   +1 more source